Kilpest Q4 results summary
3B Black bio standalone revenue of 14.5 crore Q4 FY23.
Annual non covid revenue from 3BB is 44.13 Cr for FY23 up from 26.5 cr in FY22 (+66%)
Manchester site is going to contribute greater numbers from next year, mentions about high volume annual order of Hemato-Oncology assays from a very reputed lab in UK.
Quaterly presentation has more details about tru-RAPID & tru-NGS products.
Reverse merger process in progress, next NCLT hearing on Jun 23 (Over 2 year now 
) , management believe its in final stages and should be completed soon.
NSE listing/potential buyback will be done once merger is completed.
Personal opinion: Company is very technologically capable and has right business approach focusing on Europe and other affluent countries. My confidence in the management increased with the way they handled huge profit they received from Covid, they are looking for acquiring company in similar business area but only if it meet internal IRR criteria. They announced plan for an acquisition in January, but cancelled it after due diligence.
Communication is poor (no earnings call) and reverse merger situation is quite frustrating. Other than that looks like a decent candidate for long term compounding.
Disclaimer- Invested and everything mentioned above is personal opinion, not a stock recommendation. Please do your due diligence before investing.
| Subscribe To Our Free Newsletter |
